Biomarker Testing in Lung Cancer: Clinician Checklists

Establishing a systematic biomarker testing program for eligible patients takes both time and collaboration across specialties.

The programmatic/institutional checklist details key objectives for multidisciplinary teams, enabling clear expectations and processes across hand-offs to aid in the testing process.

In addition, the case-by-case checklist helps guide physicians to ensure timely and comprehensive biomarker testing for individual patients.

DOWNLOAD INSTITUTIONAL CHECKLIST »

DOWNLOAD CASE-BY-CASE CHECKLIST »

References

1. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. Mar 2018;142(3):321-346. DOI: https://doi.org/10.5858/arpa.2017-0388-CP
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. version 3.2023. 2023 March 01.
3. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711-1723. DOI: https://doi.org/10.1056/NEJMoa2027071
4. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344-1357. DOI: https://doi.org/10.1016/s0140-6736(21)02098-5
5. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973-1985. DOI: https://doi.org/10.1056/NEJMoa2202170
6. Fox AH, Nishino M, Osarogiagbon RU, et al. Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. CA Cancer J Clin. 2023. DOI: https://doi.org/10.3322/caac.21774
7. Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019;8(3):286-301.
8. Mazer R. Clinical laboratory compliance issues. J Healthcare Compliance. 2018;20(5):21-32, 59-60.
9. Ray MA, Faris NR, Fehnel C, et al. Survival impact of an enhanced multidisciplinary thoracic oncology conference in a regional community health care system. JTO Clinical and Research Reports. 2021;2(8):100203. DOI: https://doi.org/10.1016/j.jtocrr.2021.100203
10. Denton E, Conron M. Improving outcomes in lung cancer: the value of the multidisciplinary health care team. J Multidiscip Healthc. 2016;9:137-44. DOI: https://doi.org/10.2147/jmdh.S76762
11. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2013;143(5):e211S-e250S. DOI: https://doi.org/10.1378/chest.12-2355